[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607590":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":33,"locations":39,"responsibleParty":55,"collaborators":10,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":10,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":84,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Hydroxychloroquine group",null,"Intervention: hydroxychloroquine",[13],"Drug: Hydroxychloroquine (HCQ)",{"label":15,"type":10,"description":16,"interventionNames":17},"Methotrexate group","Intervention: methotrexate",[18],"Drug: Methotrexate (MTX)",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Hydroxychloroquine (HCQ)","400 mg orally once daily",[9],[26],"Plaquenil",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Methotrexate (MTX)","15 mg weekly, orally or subcutaneously (+ concomitant medication: Folic acid 10 mg once weekly, taken 24 hours after MTX)",[15],[32],"MTX",[34],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Mathias Willaert, MD","CONTACT","+31 10 704 01 10","FFA@erasmusmc.nl",[40],{"facility":41,"status":10,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Erasmus MC University Medical Center","Rotterdam","South Holland","3015GD","Netherlands","NL",{"type":48,"coordinates":49},"Point",[50,51],4.47917,51.9225,{"lat":51,"lon":50},[54],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Rick Waalboer-Spuij, MD, PhD","Principal Investigator","100607590","the-effectiveness-of-hydroxychloroquine-versus-methotrexate-in-the-treatment-of-frontal-fibrosing-alopecia-in-routine-clinical-care-a-patient-preference-trial-ffa-trial-100607590",false,"NCT07190534","The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)","The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of frontal fibrosing alopecia (FFA)\n* Willing and able to provide written informed consent\n* Adequate understanding of the Dutch language\n* No known contraindications or allergies to hydroxychloroquine (HCQ) or methotrexate (MTX)\n\nExclusion Criteria:\n\n* Histopathological different diagnosis than FFA.\n* Inability to adhere to the study protocol, including medication intake, clinic visits, and questionnaire completion.\n* Patients who are ineligible for the HCQ arm (due to contraindications), are automatically included in the MTX arm.\n\nContraindications HCQ: retinopathy and\u002For maculopathy\u002Fmyasthenia gravis\u002Fbody weight less than 35 kg\n\n\\- Patients who are ineligible for the MTX arm (due to contraindications), are automatically included in the HCQ arm.","ALL","18 Years",{"count":69,"type":70},50,"ESTIMATED","OBSERVATIONAL","Frontal fibrosing alopecia (FFA) is a type of scarring hair loss that mostly affects women and causes permanent hair loss. Two medicines, hydroxychloroquine (HCQ) and methotrexate (MTX), are often used to treat FFA, but it is not yet clear which treatment works better. This study aims to compare the effects of HCQ and MTX in everyday clinical care.\n\nAdults with FFA who choose to start either HCQ or MTX and will be followed for up to 48 weeks.\n\nThe main goal is to see how well each medicine helps reduce disease activity, measured by a tool called the Frontal Fibrosing Alopecia Severity Score (FFASS) after 6 months. At each clinic visit, participants will also complete short questionnaires about symptoms, quality of life, and general well-being.\n\nBy collecting this information, the study hopes to provide better evidence about how well HCQ and MTX work for FFA, which may help guide future treatment recommendations.",[74,75],"Frontal Fibrosing Alopecia","Cicatricial Alopecia",[77,78,79,80,81,82,83],"Frontal fibrosing alopecia","FFA","Cicatricial alopecia","Scarring alopecia","Hair disease","hydroxychloroquine","methotrexate","NOT_YET_RECRUITING","2025-09-26",{"date":87,"type":88},"2025-09-29","ACTUAL",{"date":90,"type":70},"2025-11",{"date":92,"type":70},"2027-05",{"name":5,"class":6},1]